antitumor agent

Antitumor agent-19 is a modulator of tumor-associated macrophages with EC50s of 17.18 μM and 18.87 μM in the RAW 264.7 cells and the BMDM cells.

Antitumor agent-2 has anti-inflammatory and anti-tumor activity and can be used to study cancer.

Antitumor agent-87 is a potent compound exhibiting high antitumoral activity, with a Ki value of 0.23 µM for CYP1A1. It demonstrates antiproliferative effects and induces cell cycle arrest at the G2 M phase, underscoring its effectiveness as an antitumor agent.

(2E)-3-(3,5-dimethoxyphenyl)-1-(2-methoxyphenyl)prop-2-en-1-one is also known as DMPVP.It is a novel synthetic compound belonging to the class of cathinones that is psychoactive.

Antitumor agent-4 is a butenylphenyl phosphate derivative, is an agent of mammary cancer and anovulatory sterility.

Antitumor agent-3, a potent compound, comprises a novel imidazopyridine with excellent antitumor activity as its active ingredient.

Antitumor agent-185 (compound 3) exhibits significant antitumor effects, effectively inhibiting tumor growth and extending the survival period of mice in vivo.

Antitumor Agent-184 (compound 12aa) triggers apoptosis in various cell lines, exhibiting IC50 values of 2.35 μM in B16-F10 cells, 7.32 μM in 4T1 cells, and 10.31 μM in CT26 cells.

Antitumor agent-188 (compound C6) exhibits α-glucosidase inhibitory activity and anticancer properties. It induces excessive ROS production, thereby triggering oxidative stress.

Antitumor agent-189 (Compound DN4) is an effective anticancer drug. It inhibits the proliferation, adhesion, and invasion of A498 cells, with an IC50 of 1.94 μM. Additionally, Antitumor agent-189 suppresses angiogenesis and tumor growth in heterotopic xenograft models of A498 cells.

Antitumor agent-187 (compound I) is an isoflavone derivative with antitumor activity. It exhibits IC50 values of 5.23 μM and 2.63 μM against A2780 and SKOV3 cell lines, respectively.

Antitumor agent-109 (compound 6) is an inhibitor of CD44-targeted hyaluronic acid (HY-B0633A).

Antitumor agent-160 (compound Ia) is a derivative of the antifungal agent PHENALENONE and exhibits antitumor activity.

Antitumor agent-192 (Compound 2f) is a β-carboline antitumor compound. It induces autophagy in HCT116 cells via the ATG5 ATG7 pathway. The IC50 of Antitumor agent-192 against human tumor cell lines is below 5 μM, and it significantly inhibits tumor growth and reduces tumor weight in xenograft mouse models of colorectal cancer.

Antitumor agent-191 (Compound 7) exhibits antiviral activity against HSV-1 and HIV, with EC50 values of 0.03 μM and 0.81 μM, respectively. It also demonstrates potential antitumor properties by inhibiting cancer cell lines HepG2, WI-38, Vero, and MCF-7, with IC50 values of 19.6, 39.3, 18.3, and 28 μM, respectively.

Antitumor agent-196 (Compound 6a (β, β, β)) is an artemisinin-based oligomer with anticancer properties, exhibiting an IC50 of 90 nM against MCF-7 breast cancer cells. This compound induces apoptosis by modulating the Bax-caspase 3 signaling pathway and triggers ferroptosis by regulating key signaling molecules (including GPX4). Antitumor agent-196 shows potential for cancer research applications.

Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.

Antitumor agent-198 (Compound A3) exhibits cytotoxicity in head and neck squamous cell carcinoma (HNSCC) cells, effectively inhibiting the proliferation of CAL27, HN6, HN30, SCC9, and SCC25, with an IC50 ranging from 4 nM to 77 nM. Additionally, Antitumor agent-198 suppresses HNSCC cell migration, arrests the cell cycle, and induces apoptosis.

Antitumor agent-21 (TRX818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities.

Antitumor agent-28 is a compound that specifically targets and inhibits the activity of the ataxia telangiectasia mutated (ATM) kinase. By doing so, it effectively impedes the progression of ATM-mediated diseases and demonstrates significant anti-cancer activity.

Antitumor agent-23 exhibits potent antitumoral activity, as demonstrated by its GI50 values of 38, 48, 5, 27, 80, and 28 nM against the lymphoma cell lines GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI respectively.

Antitumor agent-68 is a potent tubulin inhibitor exhibiting significant antitumor activity, with IC 50 values of 3.6 μM for HeLa and 3.8 μM for MCF-7 cells. It also demonstrates good scavenging activity of ROS and DPPH radicals in a dose-dependent manner [1].

Antitumor agent-43 (Compound 4B) is a potent antitumor compound that induces cell cycle arrest at the G2 M phase, with an IC₅₀ of 0.5 μM for T-24 cells [1].

Antitumor agent-50 (compound 1a) is a thiazolidinone. Antitumor agent-50 is an effective antitumor agent that has the potential for the research of osteosarcoma (OS) [1].